NCT03074006View on ClinicalTrials.gov

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

TEW-7197

50mg tablets (doses will be determined through dose-escalation part)

Trial Locations (3)

10461

Site 01, The Bronx

21201

Site 02, Baltimore

33612

Site 03, Tampa

Sponsors

Lead Sponsor

MedPacto, Inc.
All Listed Sponsors
lead

MedPacto, Inc.

INDUSTRY

NCT03074006 - Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS | Biotech Hunter | Biotech Hunter